Scotiabank initiated coverage of Pfizer (PFE) with an Outperform rating and $30 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Novo Nordisk (NVO) Is Preparing to Launch Its New Weight Loss Pill – Here’s the Data
- Pharma firms spending billions on treatments based off old drugs, Bloomberg says
- FDA appoints Richard Pazdur as Director of CDER
- Pfizer call volume above normal and directionally bullish
- Cautious Optimism: Pfizer’s Strategic Initiatives and Clinical Trials Amidst Oncology Competition